SCHEMBL4862985

SCHEMBL4862985

NC(=O)c1nc(Nc2ccc(OCc3ccncc3)c(Cl)c2)c2c[c]ccc2n1

nearest known ligand 0.45

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
ERBB2 P04626 13/20 0.45
EGFR P00533 12/20 0.45
EPHA2 P29317 1/20 0.43
KDR P35968 1/20 0.43
AURKA O14965 1/20 0.41
RPS6KB1 P23443 1/20 0.41
GRM4 Q14833 1/20 0.40
STK4 Q13043 1/20 0.40
PTK6 Q13882 1/20 0.40
ERBB4 Q15303 2/20 0.39
CSF1R P07333 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4867050 0.90 EGFR (0.47) ERBB2EGFREPHA2KDRAURKA
SCHEMBL4865128 0.87 EGFR (0.59) ERBB2EGFRERBB4
SCHEMBL8488615 0.87 EGFR (0.42) ERBB2EGFRAURKARPS6KB1PTK6
SCHEMBL8150843 0.87 EGFR (0.42) ERBB2EGFRAURKARPS6KB1ERBB4
SCHEMBL4858939 0.86 AURKA (0.57) ERBB2EGFRAURKARPS6KB1STK4
SCHEMBL4866302 0.83 AURKA (0.46) ERBB2EGFRAURKARPS6KB1ERBB4
SCHEMBL2991831 0.79 DYRK1A (0.47) ERBB2EGFRKDRAURKARPS6KB1
SCHEMBL8093530 0.78 SIRT2 (0.50) ERBB2EGFRERBB4
SCHEMBL6103472 0.77 EGFR (0.48) ERBB2EGFREPHA2KDRERBB4
SCHEMBL8150035 0.77 CSNK2A1 (0.38) EGFREPHA2KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1844022-B1 QUINAZOLINE DERIVATIVES FOR INHIBITING CANCER CELL GROWTH AND METHOD FOR THE PREPARATION THEREOF HANMI SCIENCE CO LTD (KR) 2013-08-14 EP claimed
JP-2008525522-A 2008-07-17 JP claimed
US-20080009509-A1 Quinazoline Derivatives For Inhibiting Cancer Cell Growth And Method For The Preparation Thereof HANMI PHARM CO., LTD (KR) 2008-01-10 US claimed
EP-1844022-A1 QUINAZOLINE DERIVATIVES FOR INHIBITING CANCER CELL GROWTH AND METHOD FOR THE PREPARATION THEREOF Hanmi Pharm. Co., Ltd. (KR) 2007-10-17 EP claimed
WO-2006071017-A1 QUINAZOLINE DERIVATIVES FOR INHIBITING CANCER CELL GROWTH AND METHOD FOR THE PREPARATION THEREOF HANMI PHARM. CO., LTD. (KR) 2006-07-06 WO claimed
EP-1844022-B1 QUINAZOLINE DERIVATIVES FOR INHIBITING CANCER CELL GROWTH AND METHOD FOR THE PREPARATION THEREOF HANMI SCIENCE CO LTD (KR) 2013-08-14 EP disclosed
US-20080009509-A1 Quinazoline Derivatives For Inhibiting Cancer Cell Growth And Method For The Preparation Thereof HANMI PHARM CO., LTD (KR) 2008-01-10 US disclosed
EP-1844022-A1 QUINAZOLINE DERIVATIVES FOR INHIBITING CANCER CELL GROWTH AND METHOD FOR THE PREPARATION THEREOF Hanmi Pharm. Co., Ltd. (KR) 2007-10-17 EP disclosed
WO-2006071017-A1 QUINAZOLINE DERIVATIVES FOR INHIBITING CANCER CELL GROWTH AND METHOD FOR THE PREPARATION THEREOF HANMI PHARM. CO., LTD. (KR) 2006-07-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080009509-A1 Quinazoline Derivatives For Inhibiting Cancer Cell Growth And Method For The Preparation Thereof MKI67, NQO2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 ERBB2 1693/4885EGFR 1400/4885EPHA2 4530/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.